Therapeutic effect of psilocybin in addiction

Psychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs). Previous systematic reviews assessing the efficacy of psilocybin in SUDs only included clinical trials conducted in the last 25 years, but they may...

Descripción completa

Detalles Bibliográficos
Autores: van der Meer, Pim B., Fuentes, Juan J., Kaptein, Ad A., Schoones, Jan W., de Waal, Marleen M., Goudriaan, Anneke E., Kramers, Kees, Schellekens, Arnt, Somers, Metten, Bossong, Matthijs G., Batalla, Albert|||0000-0002-5010-5121
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:273234
Acceso en línea:https://ddd.uab.cat/record/273234
https://dx.doi.org/urn:doi:10.3389/fpsyt.2023.1134454
Access Level:acceso abierto
Palabra clave:Psilocybin
Hallucinogens
Substance-related disorders
Substance abuse
Drug addiction
Psychotherapy
id ES_fba271aece99ee6a3f1335c0c8a4977d
oai_identifier_str oai:ddd.uab.cat:273234
network_acronym_str ES
network_name_str España
repository_id_str
spelling Therapeutic effect of psilocybin in addictionA systematic reviewvan der Meer, Pim B.Fuentes, Juan J.Kaptein, Ad A.Schoones, Jan W.de Waal, Marleen M.Goudriaan, Anneke E.Kramers, KeesSchellekens, ArntSomers, MettenBossong, Matthijs G.Batalla, Albert|||0000-0002-5010-5121PsilocybinHallucinogensSubstance-related disordersSubstance abuseDrug addictionPsychotherapyPsychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs). Previous systematic reviews assessing the efficacy of psilocybin in SUDs only included clinical trials conducted in the last 25 years, but they may have missed clinical trials assessing the efficacy of psilocybin that were conducted before the 1980s, given much research has been done with psychedelics in the mid-20th century. In this systematic review, we specifically assessed the efficacy of psilocybin in patients with a SUD or non-substance-related disorder with no publication date restrictions in our search strategy. A systematic literature search was performed according to Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines from the earliest published manuscript up to September 2, 2022, in seven electronic databases, including clinical trials in patients with a SUD or non-substance-related disorder evaluating the efficacy of psilocybin. A total of four studies (six articles, of which two articles were long-term follow-up results from the same trial) were included in this systematic review. Psilocybin-assisted therapy was administered to n = 151 patients in a dose ranging from 6 to 40 mg. Three studies focused on alcohol use disorder, and one study on tobacco use disorder. In a pilot study (n = 10), the percentage of heavy drinking days decreased significantly between baseline and weeks 5-12 (mean difference of 26.0, 95% CI = 8.7-43.2, p = 0.008). In another single-arm study (n = 31), 32% (10/31) became completely abstinent from alcohol (mean duration of follow-up 6 years). In a double-blind, placebo-controlled randomized controlled trial (RCT, n = 95), the percentage of heavy drinking days during the 32-week double-blind period was significantly lower for psilocybin compared to placebo (mean difference of 13.9, 95% CI = 3.0-24.7, p = 0.01). In a pilot study (n = 15), the 7-day point prevalence of smoking abstinence at 26 weeks was 80% (12/15), and at 52 weeks 67% (10/15). Only one RCT and three small clinical trials were identified assessing the efficacy of psilocybin combined with some form of psychotherapy in patients with alcohol and tobacco use disorder. All four clinical trials indicated a beneficial effect of psilocybin-assisted therapy on SUD symptoms. Larger RCTs in patients with SUDs need to evaluate whether psilocybin-assisted therapy is effective in patients with SUD. 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/273234https://dx.doi.org/urn:doi:10.3389/fpsyt.2023.1134454reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2732342026-06-06T12:50:31Z
dc.title.none.fl_str_mv Therapeutic effect of psilocybin in addiction
A systematic review
title Therapeutic effect of psilocybin in addiction
spellingShingle Therapeutic effect of psilocybin in addiction
van der Meer, Pim B.
Psilocybin
Hallucinogens
Substance-related disorders
Substance abuse
Drug addiction
Psychotherapy
title_short Therapeutic effect of psilocybin in addiction
title_full Therapeutic effect of psilocybin in addiction
title_fullStr Therapeutic effect of psilocybin in addiction
title_full_unstemmed Therapeutic effect of psilocybin in addiction
title_sort Therapeutic effect of psilocybin in addiction
dc.creator.none.fl_str_mv van der Meer, Pim B.
Fuentes, Juan J.
Kaptein, Ad A.
Schoones, Jan W.
de Waal, Marleen M.
Goudriaan, Anneke E.
Kramers, Kees
Schellekens, Arnt
Somers, Metten
Bossong, Matthijs G.
Batalla, Albert|||0000-0002-5010-5121
author van der Meer, Pim B.
author_facet van der Meer, Pim B.
Fuentes, Juan J.
Kaptein, Ad A.
Schoones, Jan W.
de Waal, Marleen M.
Goudriaan, Anneke E.
Kramers, Kees
Schellekens, Arnt
Somers, Metten
Bossong, Matthijs G.
Batalla, Albert|||0000-0002-5010-5121
author_role author
author2 Fuentes, Juan J.
Kaptein, Ad A.
Schoones, Jan W.
de Waal, Marleen M.
Goudriaan, Anneke E.
Kramers, Kees
Schellekens, Arnt
Somers, Metten
Bossong, Matthijs G.
Batalla, Albert|||0000-0002-5010-5121
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Psilocybin
Hallucinogens
Substance-related disorders
Substance abuse
Drug addiction
Psychotherapy
topic Psilocybin
Hallucinogens
Substance-related disorders
Substance abuse
Drug addiction
Psychotherapy
description Psychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs). Previous systematic reviews assessing the efficacy of psilocybin in SUDs only included clinical trials conducted in the last 25 years, but they may have missed clinical trials assessing the efficacy of psilocybin that were conducted before the 1980s, given much research has been done with psychedelics in the mid-20th century. In this systematic review, we specifically assessed the efficacy of psilocybin in patients with a SUD or non-substance-related disorder with no publication date restrictions in our search strategy. A systematic literature search was performed according to Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines from the earliest published manuscript up to September 2, 2022, in seven electronic databases, including clinical trials in patients with a SUD or non-substance-related disorder evaluating the efficacy of psilocybin. A total of four studies (six articles, of which two articles were long-term follow-up results from the same trial) were included in this systematic review. Psilocybin-assisted therapy was administered to n = 151 patients in a dose ranging from 6 to 40 mg. Three studies focused on alcohol use disorder, and one study on tobacco use disorder. In a pilot study (n = 10), the percentage of heavy drinking days decreased significantly between baseline and weeks 5-12 (mean difference of 26.0, 95% CI = 8.7-43.2, p = 0.008). In another single-arm study (n = 31), 32% (10/31) became completely abstinent from alcohol (mean duration of follow-up 6 years). In a double-blind, placebo-controlled randomized controlled trial (RCT, n = 95), the percentage of heavy drinking days during the 32-week double-blind period was significantly lower for psilocybin compared to placebo (mean difference of 13.9, 95% CI = 3.0-24.7, p = 0.01). In a pilot study (n = 15), the 7-day point prevalence of smoking abstinence at 26 weeks was 80% (12/15), and at 52 weeks 67% (10/15). Only one RCT and three small clinical trials were identified assessing the efficacy of psilocybin combined with some form of psychotherapy in patients with alcohol and tobacco use disorder. All four clinical trials indicated a beneficial effect of psilocybin-assisted therapy on SUD symptoms. Larger RCTs in patients with SUDs need to evaluate whether psilocybin-assisted therapy is effective in patients with SUD.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/273234
https://dx.doi.org/urn:doi:10.3389/fpsyt.2023.1134454
url https://ddd.uab.cat/record/273234
https://dx.doi.org/urn:doi:10.3389/fpsyt.2023.1134454
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425347870588928
score 15,300724

Similares en LA Referencia